Can Precigen (PGEN) Stock Reach $13.65?

Key Takeaways

• The central target of $13.65 is the arithmetic mean of three current, individually verifiable analyst price targets ($11, $12, and $18), rounded to a reader-friendly level.
• At the last regular-session close of $6.94, reaching $13.65 would require a gain of roughly +97% — a very large move that amounts to a near-doubling of the share price.
• The individual targets range from a low of $11 to a high of $18, reflecting genuine disagreement about the pace and durability of the commercial ramp.
• All three target-setting analysts rate the stock Buy or Outperform, but the broader analyst community also includes Neutral views.
• The strongest supporting factors are the commercial launch of the company's first approved therapy, Papzimeos, sharply rising revenue, and a return to quarterly profitability.
• The biggest risks are shareholder dilution, an unprofitable trailing twelve-month result, heavy short interest, and elevated valuation multiples.
• For deeper context, explore Precigen's Major News, Today's Price Move, Forecast, and Earnings pages.
• Discover Trending AI Robots to monitor momentum and signal-driven trading strategies.

Analyst Price Targets and Consensus View

Precigen, Inc. (PGEN) is a Maryland-based gene- and cell-therapy biotechnology company, not an ETF. Its current analyst coverage is thin, which is common for early commercial-stage biotechs. The most recent, individually verifiable 12-month targets are $11 from Citizens JMP (May 2026), $12 from B. Riley Securities (September 2026), and $18 from H.C. Wainwright (October 2026). The arithmetic mean of these three is about $13.67, which rounds to the $13.65 central target used here; the low-to-high range is $11 to $18.

All three firms rate the stock Buy or Outperform, but their reasoning differs in emphasis. H.C. Wainwright raised its target to $18 from $14 after a second-quarter earnings beat, while B. Riley initiated coverage with a Buy, framing Precigen as a newly commercial-stage immuno-oncology company. Separately, data providers such as S&P Global and MarketBeat report slightly different consensus averages (roughly $13.65–$13.67) because they use different analyst sets and time windows. That spread between $11 and $18 underscores how much depends on execution rather than on a single valuation method.

Current Market Position and Path Toward the Target

The shares closed the regular session at $6.94 on October 30, 2026, near the middle of a 52-week range of roughly $3.04 to $8.98, and traded sharply lower in after-hours activity — a reminder of the stock's volatility. Reaching $13.65 would require an increase of approximately 97%, a very large move by any standard. The path would likely be driven by sustained commercial revenue growth for Papzimeos (the company's FDA-approved immunotherapy for recurrent respiratory papillomatosis, or RRP), continued margin improvement, and progress in the broader AdenoVerse and UltraCAR-T pipelines. On a trailing basis the company is still unprofitable, so the target rests heavily on forward growth and scale rather than current earnings.

What Could Support a Move Toward the Target

• Commercial traction: Papzimeos generated about $53 million in revenue in the second quarter of 2026, and total quarterly revenue of roughly $55 million rose more than 200% year over year.
• Return to profitability: Precigen reported net income of about $20 million in Q2 2026, its first profitable quarter since 2020.
• Regulatory moat: Papzimeos holds orphan-drug exclusivity as the first approved therapy for adult RRP, and a European marketing application has been submitted.
• Rising estimates: Analysts have repeatedly raised targets and revenue forecasts as launch data has exceeded expectations.
• Pipeline optionality: PRGN-2009 (HPV+ solid tumors) and the UltraCAR-T programs represent longer-dated growth avenues beyond the lead product.

What Could Prevent the Target From Being Reached

• Dilution: Shares outstanding rose about 18% year over year, and the sharp after-hours decline suggests the market is sensitive to additional capital raises.
• Lack of trailing profitability: Trailing twelve-month net income remains deeply negative, and free cash flow is negative.
• Valuation: At roughly 28 times trailing sales and more than 7 times forward sales, expectations are already elevated.
• Short interest: About 13% of shares outstanding are sold short, which can amplify both rallies and sell-offs.
• Competition and execution risk: Rival candidates in RRP and the broader oncology space, plus the inherent uncertainty of a young commercial launch, could slow the ramp.

Technical Levels and Market Structure

The stock sits below its 50-day moving average near $7.22 but above its 200-day moving average near $5.27, a mixed long-term picture. The 52-week range of $3.04 to $8.98 means the prior high near $9 is a meaningful resistance zone on the way to double digits, while the $5 level and the 200-day average represent nearby support. A decisive move above the $9 area could open the door toward the psychological $10 and $12–$13 levels, but those zones remain far from the current price.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a research horizon of roughly 12 months, though the firms here do not all disclose identical time frames. Investors should watch the company's quarterly earnings report on November 4, 2026, for Papzimeos revenue, gross margins, and any commentary on cash needs and dilution. Additional catalysts include European regulatory decisions, pipeline data readouts, analyst target revisions, and any announcements regarding capital raises or partnership deals. None of these offers a definitive forecast of the share price.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening allows. Exploring the signal platform can complement fundamental research with a systematic, data-driven view of short-term price behavior.

Final Assessment

The $13.65 central target — the average of three verified analyst price targets — implies roughly a 97% gain from the last close of $6.94, a very large move that would require Precigen to sustain its commercial momentum, convert revenue growth into durable profitability, and fund its plans without excessive dilution. The bull case rests on Papzimeos traction, orphan-drug exclusivity, and a return to quarterly profits, while the bear case emphasizes negative trailing earnings, rich valuation, heavy short interest, and share-count growth. The wide $11-to-$18 target range shows that analysts disagree materially on how fast the launch can scale. The target is a benchmark for what optimistic sell-side models assume, not a guarantee, and the path toward it will be shaped by upcoming earnings, pipeline data, and financing decisions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations